Literature DB >> 32709987

Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma.

So-Woon Kim1,2, Young Il Kim3, Bilal Mustafa4, Mi-Ju Kim5, Gowun Jeong6, Sung-Min Ahn7, Seok-Byung Lim3, Chang Sik Yu3, Jin Cheon Kim3, Seung-Mo Hong8, In Ja Park9.   

Abstract

Anorectal malignant melanoma (ARMM) is a rare disease with poor prognosis. Determining ARMM prognosis precisely is difficult due to the lack of proper assessment techniques. Immunotherapy has proven effective against cutaneous malignant melanoma and may show efficacy in ARMM. Herein, we assessed the immune profile of ARMM to identify possible prognostic biomarkers. Twenty-two ARMM formalin-fixed and paraffin-embedded samples were evaluated using an nCounter® PanCancer Immune Profiling Panel. Validation was performed through immunohistochemical staining for CD3, CD8, Foxp3, CD68, CD163, and PD-L1. RNA analysis revealed significantly decreased scores for pathways involved in cell regulation and function, as well as chemokines, in recurrent patients compared to nonrecurrent patients. In cell-type profiling, the recurrent cases displayed significantly low tumor infiltrating lymphocyte (TIL) scores. Recurrence/death prediction models were defined using logistic regression and showed significantly lower scores in recurrent and deceased patients (all, P < 0.001) compared to those in nonrecurrent and surviving patients. The high total TIL and tumor-associated macrophage (TAM) groups had significantly better overall survival outcomes compared to the low total TIL and TAM groups (P = 0.007 and P = 0.035, respectively). In addition, the presence of CD3 + TILs in the invasion front was an independent favorable prognostic indicator (P = 0.003, hazard ratio = 0.21, 95% confidential interval, 0.01-0.41). Patients with inflamed or brisk-infiltration type tumors also had a significantly better overall survival than that of patients with immune-desert/excluded and absent/non-brisk type tumors (P = 0.03 and P = 0.0023, respectively). In conclusion, TILs have a strong prognostic value in ARMM, and the quantification of TILs and an analysis of the TIL phenotype and infiltration pattern during pathological diagnosis are essential to guide treatment strategies and accurate prognosis in ARMM.

Entities:  

Year:  2020        PMID: 32709987     DOI: 10.1038/s41379-020-0633-x

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  64 in total

1.  Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.

Authors:  Simon J Furney; Samra Turajlic; Gordon Stamp; Mahrokh Nohadani; Anna Carlisle; J Meirion Thomas; Andrew Hayes; Dirk Strauss; Martin Gore; Joost van den Oord; James Larkin; Richard Marais
Journal:  J Pathol       Date:  2013-07       Impact factor: 7.996

2.  BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.

Authors:  Burkhard M Helmke; Jan Mollenhauer; Christel Herold-Mende; Axel Benner; Marianne Thome; Nikolaus Gassler; Wolfgang Wahl; Stefan Lyer; Annemarie Poustka; Herwart F Otto; Martin Deichmann
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

3.  Determinants of BRAF mutations in primary melanomas.

Authors:  Janet L Maldonado; Jane Fridlyand; Hetal Patel; Ajay N Jain; Klaus Busam; Toshiro Kageshita; Tomomichi Ono; Donna G Albertson; Dan Pinkel; Boris C Bastian
Journal:  J Natl Cancer Inst       Date:  2003-12-17       Impact factor: 13.506

Review 4.  Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer Center.

Authors:  M S Brady; J P Kavolius; S H Quan
Journal:  Dis Colon Rectum       Date:  1995-02       Impact factor: 4.585

5.  Anorectal amelanotic melanoma.

Authors:  A Hillenbrand; T F E Barth; D Henne-Bruns; A Formentini
Journal:  Colorectal Dis       Date:  2007-10-18       Impact factor: 3.788

6.  Absence of BRAF mutations in UV-protected mucosal melanomas.

Authors:  R H Edwards; M R Ward; H Wu; C A Medina; M S Brose; P Volpe; S Nussen-Lee; H M Haupt; A M Martin; M Herlyn; S R Lessin; B L Weber
Journal:  J Med Genet       Date:  2004-04       Impact factor: 6.318

7.  Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.

Authors:  Yoram Cohen; Eli Rosenbaum; Shahnaz Begum; David Goldenberg; Clemens Esche; Ofer Lavie; David Sidransky; William H Westra
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

8.  Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: A retrospective analysis of 75 patients.

Authors:  Tim Schaefer; Imke Satzger; Ralf Gutzmer
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

Review 9.  Anorectal mucosal melanoma.

Authors:  Giulia Malaguarnera; Roberto Madeddu; Vito Emanuele Catania; Gaetano Bertino; Luca Morelli; Rosario Emanuele Perrotta; Filippo Drago; Michele Malaguarnera; Saverio Latteri
Journal:  Oncotarget       Date:  2018-01-02

10.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Authors:  Michael Krauthammer; Yong Kong; Byung Hak Ha; Perry Evans; Antonella Bacchiocchi; James P McCusker; Elaine Cheng; Matthew J Davis; Gerald Goh; Murim Choi; Stephan Ariyan; Deepak Narayan; Ken Dutton-Regester; Ana Capatana; Edna C Holman; Marcus Bosenberg; Mario Sznol; Harriet M Kluger; Douglas E Brash; David F Stern; Miguel A Materin; Roger S Lo; Shrikant Mane; Shuangge Ma; Kenneth K Kidd; Nicholas K Hayward; Richard P Lifton; Joseph Schlessinger; Titus J Boggon; Ruth Halaban
Journal:  Nat Genet       Date:  2012-07-29       Impact factor: 38.330

View more
  2 in total

Review 1.  Biomedical features and therapeutic potential of rosmarinic acid.

Authors:  Saba Noor; Taj Mohammad; Malik Abdul Rub; Ali Raza; Naved Azum; Dharmendra Kumar Yadav; Md Imtaiyaz Hassan; Abdullah M Asiri
Journal:  Arch Pharm Res       Date:  2022-04-07       Impact factor: 6.010

Review 2.  Functional and Therapeutic Significance of Tumor-Associated Macrophages in Colorectal Cancer.

Authors:  Yitong Li; Zhenmei Chen; Jiahao Han; Xiaochen Ma; Xin Zheng; Jinhong Chen
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.